Skip to main content
Medpace Holdings, Inc. logo

Medpace Holdings, Inc. — Investor Relations & Filings

Ticker · MEDP ISIN · US58506Q1094 LEI · 549300H8TYEUVTW14A54 US Professional, scientific and technical activities
Open in API
Filings indexed 859 across all filing types
Latest filing 2018-04-30 Earnings Release
Country US United States of America
Listing US MEDP

About Medpace Holdings, Inc.

https://investor.medpace.com/

Medpace Holdings, Inc. is a scientifically-driven, global, full-service clinical contract research organization (CRO) that provides Phase I-IV clinical development services. The company serves the biotechnology, pharmaceutical, and medical device industries, with a mission to accelerate the development of safe and effective medical therapeutics. Medpace employs a disciplined operating approach that leverages regulatory and therapeutic expertise. Its services include clinical pharmacology, central laboratory, bioanalytical, ECG core lab, and imaging core labs. The company has expertise across major therapeutic areas, including oncology, cardiology, metabolic disease, endocrinology, central nervous system, and anti-viral and anti-infective diseases.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filing with the SEC, dated April 30, 2018, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2018. The text states that the press release is furnished as an exhibit and posted on the company's website. The document itself does not contain detailed financial statements or substantive financial data but rather announces the release of such information. The document length is 3487 characters, which is relatively short and consistent with an announcement rather than a full report. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release of earnings) rather than the report itself. Therefore, the appropriate classification is Earnings Release (ER).
2018-04-30 English
DEFA14A
Remuneration Information Classification · 95% confidence The document is a Schedule 14A filing, which is a definitive proxy statement or definitive additional materials related to a shareholder meeting. It includes information about the annual meeting, voting instructions, election of directors, and ratification of the independent auditor. It does not contain financial statements or detailed financial analysis, but rather proxy solicitation materials for shareholders to vote. The document is not the actual Annual Report (10-K) or the full Proxy Statement (PSI), but rather additional proxy materials. Given the content and the SEC form type (Schedule 14A), the most appropriate classification is 'DEF 14A' which covers remuneration and proxy-related information. The document length (8847 characters) and content confirm it is not a brief announcement or a full report but proxy solicitation materials.
2018-04-05 English
DEF 14A
Proxy Solicitation & Information Statement
2018-04-05 English
FORM 4
Director's Dealing
2018-03-02 English
FORM 4
Director's Dealing
2018-03-02 English
FORM 4
Director's Dealing
2018-03-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.